Sign In
Buy NVTA
$0.0190
+0 (+0%)
At Close: May 13, 2024
Qiagen N : provides information on potential capital gain from its minority investment in ArcherDX | MarketScreener
05:57pm, Tuesday, 23'rd Jun 2020QIAGEN N.V.: QIAGEN provides information on potential capital gain from its minority investment in ArcherDX | MarketScreener
05:50pm, Tuesday, 23'rd Jun 2020NASDAQ Ends at Record Close Again with Some Help from Apple
12:00am, Tuesday, 23'rd Jun 2020
Stocks Analysis by Zacks Investment Research covering: Intel Corporation, Microsoft Corporation, Lennar Corporation, KB Home. Read Zacks Investment Research's latest article on Investing.com
Invitae Acquiring ArcherDX, Stock Skyrockets 45% | The Motley Fool
10:41pm, Monday, 22'nd Jun 2020
The combination of the two companies will create a genetics powerhouse.
Biotech ETFs Surge After Invitae Acquires ArcherDX | ETF Trends
09:35pm, Monday, 22'nd Jun 2020
Biotechnology sector-related exchange traded funds were among the leaders on Monday after Invitae Corp. (NYSE: NVTA) announced a $1.4 billion deal for ArcherDX
Xconomy: Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx
09:15pm, Monday, 22'nd Jun 2020
Cancer treatment is increasingly moving toward targeted therapies based on the genetics of a patient’s tumor and Invitae is ensuring it gets its share of
Invitae Surges on $1.4B Acquisition of ArcherDX | The Motley Fool
05:33pm, Monday, 22'nd Jun 2020
The genetic testing company pulled the trigger on its largest acquisition yet.
Price Over Earnings Overview: Invitae
02:38pm, Monday, 22'nd Jun 2020
In the current session, Invitae Inc. (NYSE: NVTA) is trading at $24.86, after a 33.49% spike. Over the past month, the stock increased by 50.48%, and in the past year, by 20.47%. With performance like
Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session
12:42pm, Monday, 22'nd Jun 2020
Invitae (NVTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Invitae : and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology | MarketScreener
11:01am, Monday, 22'nd Jun 2020Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
11:00am, Monday, 22'nd Jun 2020
Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agree
Global Non-Invasive Prenatal Testing Market Assessment 2020-2025 - ResearchAndMarkets.com
12:00am, Thursday, 18'th Jun 2020
The
No Reckoning For Wall Street's Worst
12:06pm, Tuesday, 16'th Jun 2020
US corporate debt is heading for 50% of GDP. That's not just a new record… it’s other-worldly. The S&P 500 SPDR Trust (SPY) used to be highly correlated with pr
Retail Therapy Is Still a World Away
11:17am, Tuesday, 16'th Jun 2020
(Bloomberg Opinion) -- There was great anticipation about what shopping would be like when non-essential stores finally reopened their doors in England on Monday. It quickly became clear that we won
No Reckoning For Wall Street’s Worst
12:00am, Tuesday, 16'th Jun 2020
Stocks Analysis by Gary Gordon covering: Logitech International SA, SPDR S&P 500, Exxon Mobil Corp, Verizon Communications Inc. Read Gary Gordon's latest article on Investing.com
